BridgeBio Pharma Inc
BridgeBio Pharma Inc (BBIO) Options Open Interest
BBIO options open interest is 47,231 contracts. The 2-week average daily volume is 1,261 contracts across the chain.
Read more
Monitoring BBIO open interest helps you see where real money is positioned on BridgeBio Pharma Inc's options and which strikes are attracting the most commitment from traders. BridgeBio Pharma Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor BBIO options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising BBIO options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect BridgeBio Pharma Inc to settle.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where BBIO open interest is concentrated. Our scanner maps BridgeBio Pharma Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade BridgeBio Pharma Inc's options open interest as the signal it is, not as an afterthought.
| 70.00 | — | 0.15 | 0.15 | 80% | +0.1311 | 720 |
| 72.50 | — | 0.75 | 0.75 | 212% | +0.2216 | 422 |
| 87.50 | — | 2.15 | 2.15 | 667% | +0.2209 | 398 |
| 75.00 | — | 0.60 | 0.60 | 246% | +0.1663 | 316 |
| 67.50 | 0.50 | 2.75 | 1.63 | 148% | +0.4956 | 228 |
| 75.00 | 5.90 | 9.40 | 7.65 | 26% | -1.0000 | 389 |
| 80.00 | 10.70 | 14.00 | 12.35 | 51% | -1.0000 | 336 |
| 70.00 | 0.90 | 3.50 | 2.20 | 10% | -1.0000 | 56 |
| 72.50 | 3.40 | 7.10 | 5.25 | 105% | -0.9479 | 30 |
| 65.00 | — | 0.20 | 0.20 | 82% | -0.1574 | 13 |
As of September 17, 2026
Follow the money
Track BBIO open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.
Start your 14-day free trial→